| Title |
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, March 2018
|
| DOI | 10.2147/dddt.s155307 |
| Pubmed ID | |
| Authors |
Corrado Pelaia, Alessandro Vatrella, Andrea Bruni, Rosa Terracciano, Girolamo Pelaia |
| Abstract |
Asthma is a widespread and heterogeneous inflammatory disease of the airways, which is characterized by several different phenotypes and endotypes. In particular, eosinophilic airway inflammation is a common pathologic trait of both allergic and nonallergic asthma. The key cytokine responsible for maturation, activation, recruitment, and survival of eosinophils is interleukin (IL)-5, which is mainly produced by T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells. Therefore, for uncontrolled patients with severe eosinophilic asthma, who are not fully responsive to corticosteroids, IL-5 represents a very important molecular target for add-on biological therapies. Among these new treatments, anti-IL-5 monoclonal antibodies such as mepolizumab and reslizumab have been developed and clinically evaluated. Furthermore, benralizumab is currently the only available biologic drug that specifically binds to the IL-5 receptor, thus preventing the interaction with its ligand and the consequent pro-inflammatory effects. The effectiveness of benralizumab in improving severe eosinophilic asthma has been well-documented by many randomized controlled trials. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 70 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 17% |
| Student > Doctoral Student | 10 | 14% |
| Student > Bachelor | 8 | 11% |
| Student > Postgraduate | 4 | 6% |
| Other | 4 | 6% |
| Other | 12 | 17% |
| Unknown | 20 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 39% |
| Biochemistry, Genetics and Molecular Biology | 7 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Immunology and Microbiology | 2 | 3% |
| Mathematics | 1 | 1% |
| Other | 4 | 6% |
| Unknown | 24 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2018.
All research outputs
#16,728,456
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#1,011
of 2,268 outputs
Outputs of similar age
#212,237
of 344,853 outputs
Outputs of similar age from Drug Design, Development and Therapy
#20
of 48 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,853 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.